Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | PPP3CB | P16298 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13365362 | 0.94 | CTSS (0.45) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL1688334 | 0.94 | CTSB (0.46) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL1688332 | 0.94 | CTSB (0.46) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL13336849 | 0.94 | CYP3A4 (0.52) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL1688333 | 0.93 | CTSS (0.46) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL13336832 | 0.92 | CYP3A4 (0.53) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL7876132 | 0.92 | CYP3A4 (0.44) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL13365173 | 0.89 | CYP3A4 (0.50) | CYP3A4CTSBPPP3CB | |
| SCHEMBL7946617 | 0.88 | CYP3A4 (0.54) | CYP3A4CTSBPPP3CBCTSS | |
| SCHEMBL7937348 | 0.88 | CYP3A4 (0.54) | CYP3A4CTSBPPP3CBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012047764-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2012-04-12 | — | — | WO | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-05-13 | — | — | US | disclosed |
| WO-2010045266-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | INTERMUNE, INC. (US) | 2010-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100119479-A1 | THERAPEUTIC ANTIVIRAL PEPTIDES | SARS1, VIP, MAVS | CYP3A4 3754/4885CTSB 260/4885PPP3CB 987/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.